Interactive Online Informational and Peer Support App for Patients with Low Anterior Resection Syndrome
Launched by JEWISH GENERAL HOSPITAL · Jul 9, 2020
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
Restorative proctectomy is increasingly being performed for rectal cancer, allowing patients to avoid permanent colostomy. Low Anterior Resection Syndrome (LARS) refers to a constellation of bowel symptoms including frequency, urgency, incontinence, and clustering of bowel movements, that can affect up to 70 to 90% of patients following restorative proctectomy. Symptoms can last up to 15 years after resection. Currently, there is no standard treatment for LARS and management is symptom-based and reactive, rather than proactive. A recent focus group conducted at our institution among LARS pa...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • underwent restorative protectomy for Neo-plastic disease of the rectum
- • completed all treatment within the last 3 years
- • patients with minor or major LARS as defined with the LARS score.
- Exclusion Criteria:
- • Active chemotherapy or radiotherapy
- • Major colonic resection in addition to protectomy
- • Cannot be contacted by telephone
- • Unable to read and comprehend English/French
- • Does not have the appropriate interface to access the app
- • Unable to give clear and informed consent
About Jewish General Hospital
The Jewish General Hospital (JGH) is a leading academic health care institution in Montreal, Canada, renowned for its commitment to excellence in patient care, research, and education. As a sponsor of clinical trials, JGH leverages its state-of-the-art facilities and multidisciplinary expertise to advance medical knowledge and improve treatment outcomes across various specialties. The hospital is dedicated to fostering innovation through rigorous scientific investigation and collaboration with renowned research institutions, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements. With a focus on patient-centered research, JGH aims to translate findings into effective therapeutic strategies that enhance the quality of care for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Vancouver, British Columbia, Canada
Toronto, Ontario, Canada
Montréal, Quebec, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials